Condition: Atrial Fibrillation

The purpose of this phase 2 study is to evaluate the bleeding profile of abelacimab compared to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.

Location(s): Jacksonville (Headquarters), St. Augustine

Condition: Atrial Fibrillation, Heart Disease